PP1

PP1
Name	PP1
Caption	Serine/threonine-protein phosphatase 1 catalytic subunit
Uniprot	P62136
Organism	Homo sapiens
Length	330

PP1 Protein phosphatase 1 (PP1) is a major eukaryotic serine/threonine phosphatase involved in reversing phosphorylation signals across diverse cellular contexts. PP1 participates in cell cycle progression, synaptic plasticity, muscle contraction, and glycogen metabolism, acting downstream of kinases implicated in signal transduction events. Its activity is controlled by a large repertoire of regulatory subunits and targeting proteins that confer substrate specificity and localization.

Overview

PP1 is conserved from yeast to humans and was characterized biochemically in studies associated with C. elegans development, Drosophila melanogaster genetics, and mammalian biochemical fractionation beginning in the 1970s. Early purification efforts linked PP1 activity to control of glycogen synthase in liver and muscle, which intersected with work on Insulin signaling and Glycogen synthase kinase 3. Structural biology advances connected PP1 to the family of PPP phosphatases alongside Calcineurin, Protein phosphatase 2A, and Protein phosphatase 4.

Structure and Isoforms

The PP1 catalytic subunit adopts a conserved fold characterized by a central beta-sandwich and surrounding alpha helices; active site geometry coordinates metal ions essential for catalysis, which was elucidated in crystal structures with inhibitors and regulatory peptides solved in complex with PP1 orthologs and human catalytic cores. In mammals, three genes encode catalytic isoforms: PPP1CA, PPP1CB, and PPP1CC, which produce protein variants with tissue-preferential expression patterns highlighted in transcriptomic atlases such as those from The Human Protein Atlas and studies by ENCODE. Alternative splicing and post-translational modifications, including phosphorylation by kinases like Cyclin-dependent kinase 1 and methylation at the C terminus, modulate isoform-specific interactions. Comparative genomics links PP1 orthologs to model organisms used in functional studies: Saccharomyces cerevisiae Glc7, Schizosaccharomyces pombe Dis2, and plant homologs studied in Arabidopsis thaliana.

Biological Function and Mechanism

PP1 catalyzes dephosphorylation via a two-metal ion mechanism in which active site residues coordinate manganese or iron ions; this mechanism was clarified through collaborations among structural groups at institutions such as European Molecular Biology Laboratory and Harvard Medical School. PP1 regulates mitotic exit by counteracting mitotic kinases including Aurora B kinase and Polo-like kinase 1, and it contributes to DNA damage responses alongside factors characterized at Cold Spring Harbor Laboratory and Wellcome Sanger Institute. In neurons, PP1 opposes long-term potentiation pathways driven by Calcium/calmodulin-dependent protein kinase II and Protein kinase A, influencing learning and memory phenotypes probed in laboratories at MIT and Columbia University. In muscle and metabolic tissues, PP1 targets glycogen-targeting subunits that connect to Glycogen phosphorylase and Glycogen synthase, integrating signals from Insulin and AMP-activated protein kinase pathways.

Regulation and Interacting Proteins

PP1 specificity arises through a diverse set of regulatory and targeting proteins, often containing an RVxF docking motif first characterized in biochemical screens performed at Max Planck Institute collaborators. Well-characterized regulatory subunits include MYPT1 (myosin phosphatase target subunit), NIPP1 (nuclear inhibitor of PP1), GADD34 (growth arrest and DNA damage-inducible protein), and Spinophilin and Neurofilament-associated adaptors identified in neuroscience centers such as Stanford University. PP1 is regulated by inhibitor proteins such as Inhibitor-1 (I-1) and DARPP-32, which link PP1 activity to dopaminergic signaling studied in contexts involving National Institute of Mental Health research. PP1 localization to subcellular compartments is mediated by scaffolds and holoenzyme assembly pathways explored in proteomics initiatives at Massachusetts Institute of Technology and European Bioinformatics Institute.

Role in Disease and Therapeutic Targeting

Dysregulation of PP1 activity or mislocalization is implicated in cancer, neurodegenerative disorders, cardiac hypertrophy, and metabolic disease. Altered PP1 regulatory complexes have been reported in studies of Breast cancer and Acute myeloid leukemia, where changes in PP1 holoenzymes affect cell proliferation and checkpoint control involving p53 and RB1 pathways. In neurodegeneration, aberrant PP1 signaling influences tau phosphorylation pathways relevant to Alzheimer's disease research at centers including NIH and university neurology departments. Small-molecule and peptide-based modulators targeting PP1 regulatory interfaces have been developed in academic-industry collaborations with groups at Novartis and Pfizer; approaches include disruptors of holoenzyme assembly, substrate-mimetic inhibitors, and allosteric regulators that aim to achieve selectivity by exploiting regulatory subunit contacts characterized by crosslinking mass spectrometry performed at facilities such as EMBL-EBI.

Experimental Methods and Assays

Biochemical assays for PP1 activity include radiolabeled phosphopeptide dephosphorylation, colorimetric phosphatase assays, and mass spectrometry-based phosphoproteomics used in large-scale projects like CPTAC. Structural characterization employs X-ray crystallography and cryo-electron microscopy conducted at national facilities such as Diamond Light Source and Argonne National Laboratory. Genetic perturbation strategies include CRISPR-based knockout and RNAi screens implemented in cell lines profiled by consortia such as Broad Institute, as well as conditional knockout mouse models developed in transgenic labs at Jackson Laboratory. Interaction mapping leverages affinity purification with tandem mass spectrometry and proximity labeling approaches (BioID, APEX) applied in investigations at institutions including University of California, San Francisco.

Category:Protein phosphatases